デングワクチンの世界市場

◆英語タイトル:Dengue Vaccine Market: Contribution of NGOs for Better Vaccine Access Expected to Drive the Market in Lower Income Countries: Global Industry Analysis & Opportunity Assessment, 2017 – 2027
◆商品コード:DATA70609016
◆発行会社(調査会社):Future Market Insights
◆発行日:2017年3月
◆ページ数:98
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬
◆販売価格オプション(消費税別)
Individual PriceUSD5,000 ⇒換算¥565,000見積依頼/購入/質問フォーム
Corporate PriceUSD7,500 ⇒換算¥847,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご確認ください。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はFuture Market Insights社の日本における正規販売代理店です。Future Market Insights社の概要及び新刊レポートはこちらでご確認いただけます。
【レポートの概要】

Global dengue vaccine market revenue is expected to expand at a significant rate owing to a large unmet need
The first dengue vaccine, Dengvaxia (CYD-TDV) developed by Sanofi Pasteur is registered in 14 countries in the Latin America and Asia Pacific region. CYD-TDV vaccine is a live recombinant tetravalent dengue vaccine that is indicated as a 3 dose series of 0/6/12 month schedule. There are around five other vaccine candidates under evaluation in clinical trials, comprising other live-attenuated vaccines as well as subunit, DNA and purified inactivated vaccine candidates of which Takeda’s TAK-003 and Butantan Institute vaccine candidates are being evaluated in phase 3 clinical trials currently.

The global dengue vaccine market is estimated to be valued at nearly US$ 250 Mn in 2017 and is expected to expand at a 17.5% CAGR over the forecast period (2017–2027). The global dengue vaccine market is projected to be valued at more than US$ 1250 Mn by 2027.

Factors impacting the global dengue vaccine market

Growth of the global dengue vaccine market is mainly driven by rising burden of dengue fever in tropical regions, large unmet medical need for managing dengue burden, promising end stage vaccine pipeline, development of live attenuated tetravalent dengue vaccine, and expected local production of dengue vaccine in various countries. Other prominent factors driving revenue growth of the market are adoption/uptake of dengue vaccine by various countries in dengue endemic regions of Latin America and Asia Pacific and increased governmental interest to incorporate the vaccine in public immunisation programmes across various countries.

However, supply side infrastructure bottlenecks such as surveillance system, standardised diagnostics practice, and cold chain systems for storage of vaccine in resource constrained countries are the factors hampering the growth of the global dengue vaccine market.

Companies engaged in the development of dengue vaccine are employing strategies to incorporate dengue vaccine in public immunisation programmes and vaccines in clinical stage development are being tested for safety and efficacy in all age groups and different transmission settings.

Global Dengue Vaccine Market Attractiveness Analysis by End User, 2017 – 2027

Several governments are willing to incorporate dengue vaccine in public immunisation programmes given assured quality, safety and affordability of the vaccine in endemic countries

The Government Institutes segment is expected to dominate the global dengue vaccine market in revenue terms and the trend is projected to continue throughout the forecast period. The Government Institutes segment is estimated to account for 49.5% value share in 2017 and is projected to account for 51.9% share by the end of 2027. In terms of value, the Hospitals segment is anticipated to register a moderate CAGR of 17.3% during the forecast period. The NGOs segment is expected to remain the least attractive segment in the global dengue vaccine market in revenue terms with an attractiveness index of 0.7 over the forecast period. The NGOs segment is estimated to account for 22.5% value share in 2017 and is projected to account for 20.5% value share by the end of 2027. Analyst Viewpoint

Developing a vaccine that is effective in all age groups is expected to drive market revenue growth over the forecast period

Of late dengue vaccine candidates, which are in the late stage of development, are showing better clinical benefits in all age groups and have better dosing pattern. For instance, Takeda’s – Tak-003 dengue vaccine candidate has demonstrated acceptable safety and efficacy in different population groups with two doses (three months apart) of vaccine. Currently Dengvaxia is recommended in three doses at 0, 6, 12 months. Development of dengue vaccine that is effective for infants and children is expected to reduce the dengue burden and thereby create demand in the global dengue vaccine market.

【レポートの目次】

Table Of Content

1. Executive Summary

2. Market Introduction

2.1. Market Taxonomy

3. Global Dengue Vaccine Market Analysis Scenario

3.1. Market Size (US$ Mn) and Forecast

3.1.1. Market Size and Y-o-Y Growth

3.2.2. Absolute $ Opportunity

3.2. Market Overview

4. Market Dynamics and USPs

4.1. Macro-economic Factors

4.2. Drivers

4.2.1. Supply Side

4.2.2. Demand Side

4.3. Restraints

4.4. Opportunity

4.5. Trends

4.6. Dengue Vaccine Research Pipeline Analysis

4.7. Global Dengue Vaccine Market: Funding Scenario

4.8. Global Dengue Vaccine Market: Dengue Epidemiology Analysis

4.9. Global Dengue Vaccine Market: Dengvaxia SWOT

4.10. Global Dengue Vaccine Market: Dengvaxia Promotional Activities

4.11.Global Dengue Vaccine Market: Dengvaxia Sales Channel Strategy

4.12. Global Dengue Vaccine Market: Dengvaxia Tier-Pricing by Region

5. Global Dengue Vaccine Opportunity Analysis and Forecasts, By End User

5.1. Introduction

5.2. Basis Point Share (BPS) Analysis By End User

5.3. Y-o-Y Growth Projections By End User

5.4. Market Value Forecast By End User, 2017–2027

5.4.1. Hospitals

5.4.2. Government Institutes

5.4.3. NGOs

5.5. Prominent Trends

5.5. Market Attractiveness By End User

6. Global Dengue Vaccine Opportunity Analysis and Forecasts, By Region

6.1. Basis Point Share (BPS) Analysis By Region

6.2. Y-o-Y Growth Projections By Region

6.3. Market Value Forecast By Region

6.3.1. Latin America

6.3.2. Asia Pacific

6.3.3. Middle East and Africa (MEA)

6.3.4. Rest of the World (RoW)

6.4. Market Attractiveness By Region

7. Latin America Dengue Vaccine Opportunity Analysis and Forecast

7.1. Introduction

7.1.1. Basis Point Share (BPS) Analysis By Country

7.1.2. Y-o-Y Growth Projections By Country

7.2. Market Value Forecast By, 2016–2026

7.3. Market Value Forecast By End User, 2016–2026

7.3.1. Hospitals

7.3.2. Government Institutes

7.3.3. NGOs

7.4. Market Value Forecast By Country, 2016–2026

7.4.1. Brazil

7.4.2. Mexico

7.4.3. Venezuela

7.4.4. Rest of Latin America

7.5. Market Attractiveness Analysis

7.5.1. By End User

7.5.2. By Country

8. Asia Pacific Dengue Vaccine Opportunity Analysis and Forecast

8.1. Introduction

8.1.1. Basis Point Share (BPS) Analysis By Country

8.1.2. Y-o-Y Growth Projections By Country

8.2. Market Value Forecast By, 2016–2026

8.3. Market Value Forecast By End User, 2016–2026

8.3.1. Hospitals

8.3.2. Government Institutes

8.3.3. NGOs

8.4. Market Value Forecast By Country, 2016–2026

8.4.1. Philippines

8.4.2. Indonesia

8.4.3. Malaysia

8.4.4. Thailand

8.4.5. Vietnam

8.4.6. India

8.4.7. Rest of Asia Pacific

8.5. Market Attractiveness Analysis

8.5.1. By End User

8.5.2. By Country

9. Middle East and Africa (MEA) Dengue Vaccine Opportunity Analysis and Forecast

9.1.Introduction

9.1.1. Basis Point Share (BPS) Analysis By Country

9.1.2. Y-o-Y Growth Projections By Country

9.2.Market Value Forecast By, 2016–2026

9.3.Market Value Forecast By End User, 2016–2026

9.3.1. Hospitals

9.3.2. Government Institutes

9.3.3. NGOs

9.4.Market Value Forecast By Country, 2016–2026

9.4.1. Africas

9.4.2. GCC Countries

9.5.Market Attractiveness Analysis

9.5.1. By End User

9.5.2. By Country

10. Rest of the World (RoW) Dengue Vaccine Opportunity Analysis and Forecast

11. Competition Landscape

11.1. Company Profiles (Details – Overview, Financials, Strategy, Recent Developments)

11.1.1. Sanofi

11.1.2. Takeda Pharmaceutical Company Limited

12. Assumptions and Acronyms Used

13. Research Methodology



★調査レポート[デングワクチンの世界市場] (コード:DATA70609016)販売に関する免責事項を必ずご確認ください。
★調査レポート[デングワクチンの世界市場]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆